These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 22397370)

  • 21. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
    Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
    Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, Metabolism, and Partial Biodistribution of "Pincer Therapeutic" Nitazoxanide in Mice following Pulmonary Delivery of Inhalable Particles.
    Gupta A; Tulsankar SL; Bhatta RS; Misra A
    Mol Pharm; 2017 Apr; 14(4):1204-1211. PubMed ID: 28263078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of antituberculosis drugs after oral isolated and simultaneous administration in triple combination.
    Zítková L; Janků I; Tousek J; Papezová E; Stastná J
    Czech Med; 1983; 6(4):202-17. PubMed ID: 6420125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.
    Sharma R; Muttil P; Yadav AB; Rath SK; Bajpai VK; Mani U; Misra A
    J Antimicrob Chemother; 2007 Mar; 59(3):499-506. PubMed ID: 17242031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction.
    Ng KY; Zhou H; Zhang YL; Hybertson B; Randolph T; Christians U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 847(2):188-98. PubMed ID: 17070115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetics of isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid of rabbits.
    Walubo A; Chan K; Wong CL
    Methods Find Exp Clin Pharmacol; 1991 Apr; 13(3):199-204. PubMed ID: 2051844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-90-7) in F344/N rats and B6C3F1 mice (inhalation studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2001 Jul; (499):7-340. PubMed ID: 12087422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of the effects of rifabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers.
    Breda M; Pianezzola E; Strolin Benedetti M; Efthymiopoulos C; Carpentieri M; Sassella D; Rimoldi R
    Drug Metabol Drug Interact; 1992; 10(4):323-40. PubMed ID: 1338982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).
    Maslow JN; Mikota SK; Zhu M; Isaza R; Peddie LR; Dunker F; Peddie J; Riddle H; Peloquin CA
    J Vet Pharmacol Ther; 2005 Feb; 28(1):21-7. PubMed ID: 15720511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
    Matteelli A; Olliaro P; Signorini L; Cadeo G; Scalzini A; Bonazzi L; Caligaris S; Tomasoni L; Tebaldi A; Carosi G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11):1043-6. PubMed ID: 10587327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin.
    Li RC; Narang PK; Poggesi I; Strolin-Benedetti M
    Biopharm Drug Dispos; 1996 Apr; 17(3):223-36. PubMed ID: 8983397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
    Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NTP Toxicology and Carcinogenesis Studies of Nickel Oxide (CAS No. 1313-99-1) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Jul; 451():1-381. PubMed ID: 12594524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species.
    Bruzzese T; Rimaroli C; Bonabello A; Mozzi G; Ajay S; Cooverj ND
    Arzneimittelforschung; 2000 Jan; 50(1):60-71. PubMed ID: 10683718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.
    Lalande L; Bourguignon L; Bihari S; Maire P; Neely M; Jelliffe R; Goutelle S
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5181-9. PubMed ID: 26077251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetic characteristics of streptomycin and isoniazid administered in ultrasonic aerosols to patients with respiratory organ tuberculosis].
    Brant AL; Semenova EA
    Antibiotiki; 1981 Aug; 26(8):628-32. PubMed ID: 7294755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.